Erlotinib Unknown Status Phase 2 Trials for Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC) / Drug Therapy / Genes, EGFR Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01131429A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations